The newest study of the top 100 publications was published in December 2018 in the Journal of the American Academy of Dermatology, entitled “Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating clinical and histopathologic features, frequency, and impact on cancer therapy,” which was a single-center retrospective study evaluating the development of pemphigoid diseases (including bullous pemphigoid and linear IgA bullous) after cancer therapy (86). Here, CD274 is linked to autoimmune bullous skin disease.